MarketFools.com
  • Home
  • Business
  • Economy
  • Finance
    • Personal Finance
  • Stock Market
    • Commodities
  • Cryptocurrency
    • Bitcoin
No Result
View All Result
MARKET FOOLS
No Result
View All Result
Home Business

CURE Pharmaceutical Q3 Revenue Grows 58.9% Sequentially To $1.8M – CURE Pharmaceutical Hldg (OTC:CURR)

by Cyril M
November 22, 2022
0
CURE Pharmaceutical Q3 Revenue Grows 58.9% Sequentially To $1.8M – CURE Pharmaceutical Hldg (OTC:CURR)
325
SHARES
2.5k
VIEWS
Share on FacebookShare on Twitter



CURE Pharmaceutical Holding Corp. CURR revenue within the third quarter elevated 32.1% year-over-year and 58.9% sequentially from Q2 2022 to $1.8 million.

Q3 2022 Monetary Highlights

  • Gross revenue was $1.4 million in comparison with $914,000 in Q3 2021.

  • Gross margins for the third quarter improved by 123 foundation factors to 80.0% in 2022 in comparison with the identical interval in 2021.

  • Web loss was $3.6 million in comparison with $4.3 million in Q3 2021.

Operational Highlights

  • CURE accomplished the sale of a portion of its platform expertise mental property portfolio and associated belongings in July 2022 for $20 million of non-dilutive capital in complete consideration. The corporate retained 15 of its patents and can proceed to be an incubator for future applied sciences and patents, which it intends to monetize via the commercialization of the applied sciences via product improvement or via the licensing or sale of the applied sciences.

  • CURE’s wholly owned subsidiary, The Sera Labs, began promoting six SKUs of its Seratopical Revolution skincare line with P3P, the proprietary supply system, at 1,372 Walmart Shops in addition to on Amazon.com.

  • Sera Labs additionally has garnered placement for its oral skinny movie strip, Nutri-Strips on cabinets at CVS, Amazon.com and Goal.com. Nutri-Strips are proprietary to Sera Labs and are the results of years of analysis.

Board of Administrators and Governance Replace

In August the corporate appointed Gerald Bagg and Robert J. Costantino to its board of administrators and Costantino has additionally been appointed as chairman of CURE’s Audit Committee. Former CURE CEO Rob Davidson was appointed as chairman of the board of administrators.

Get your each day dose of cannabis news on Benzinga Hashish. Don’t miss out on any essential developments within the business.

Photograph by Mackenzie Marco on Unsplash

Associated Information

CURE Pharmaceutical Q2 2021 Revenue Spikes 700% After Increased Sales From Sera Labs Products Including A CVS Deal

 

© 2022 Benzinga.com. Benzinga doesn’t present funding recommendation. All rights reserved.

BENZINGA CANNABIS CONFERENCE

Meet the most important hashish business gamers and make offers that may push the business ahead.

That includes stay firm displays, insider panels, and unmatched entry to networking, the Benzinga Cannabis Capital Conference is the place hashish executives and entrepreneurs meet.

Be a part of us April 11-12, 2023 at Fontainebleau Miami Seaside in sunny Florida.



Source link

Tags: 1.8MCUREGrowsHldgOTCCURRPharmaceuticalRevenueSequentially
Cyril M

Cyril M

No Result
View All Result
Powered by Investing.com

Recent.

Banking Strains, Inflation Threaten Global Economic Rebound

Banking Strains, Inflation Threaten Global Economic Rebound

March 24, 2023
Venture capitalists bail on Zipmex bailout, company warns of consequences: Report

Venture capitalists bail on Zipmex bailout, company warns of consequences: Report

March 24, 2023
Bitcoin, Other Crypto See $360 Million Sold Off In Single Day

Bitcoin, Other Crypto See $360 Million Sold Off In Single Day

March 24, 2023
  • Privacy & Policy
  • Terms & Conditions
  • About us
  • Contact us

© 2022 MARKET FOOLS | All Rights Reserved

No Result
View All Result
  • Home
  • Business
  • Economy
  • Finance
    • Personal Finance
  • Stock Market
    • Commodities
  • Cryptocurrency
    • Bitcoin

© 2022 MARKET FOOLS | All Rights Reserved

Are you sure want to unlock this post?
Unlock left : 0
Are you sure want to cancel subscription?